Methods for Treating Parkinson's Disease

Abstract

The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A 2A ) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B.

1 . A method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A 2A ) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B. 
     
     
         2 . The method according to  claim 1 , wherein the A 2A  antagonist is selective over each of the other adenosine receptor subtypes A 1 , A 2B , A 3  by a factor of at least 10. 
     
     
         3 . The method according to  claim 1 , wherein the NR2B antagonist is selective over each of the other NMDA receptor subtypes NR2A, NR2C, and NR2D by a factor of at least 10. 
     
     
         4 . The method according to anyone of  claims 1  to  3  wherein the ratio of the A 2A  antagonist to the NR2B antagonist varies from between 30:1 to 1:30. 
     
     
         5 . The method according to any of the preceding claims wherein both pharmaceutical agents are administered essentially at the same time. 
     
     
         6 . The method according to any of the preceding claims wherein both pharmaceutical agents are administered together with L-Dopa. 
     
     
         7 . The method according to any of the preceding claims wherein both pharmaceutical agent are administered once a day. 
     
     
         8 . The method according to any of the preceding claims wherein the A 2A  antagonist is selected from the group comprising, istradefylline (KW-6002), BIIB014, preladenant (SCH420814), ST-1535, ASP5854, SYN-115. 
     
     
         9 . The method according to any of the preceding claims wherein the NR2B antagonist is selected from the group comprising MK-0657, Traxoprodil (CP-101,606), EVT-101, EVT-103, Radiprodil (RGH 896), 
     
     
         10 . A pharmaceutical composition comprising a therapeutically effective amount of a combination of an adenosine A 2A  receptor antagonist and a NR2B antagonist in a pharmaceutical acceptable carrier. 
     
     
         11 . A pharmaceutical composition as defined in any of the previous claim in form of a kit of parts comprising
 (a) a first containment containing a pharmaceutical formulation comprising a therapeutically effective amount of an A 2A  receptor antagonist and   (b) a second containment containing a pharmaceutical formulation comprising a therapeutically effective amount of the NR2B antagonist.